Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome
NCT01396070Phase 2Completed
- Start
- May 2011
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in mycosis fungoides (MF), Sézary syndrome (SS). Started May 2011; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT01396070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396070.